达安基因：广药集团拟受让公司2.33亿股股份

Core Viewpoint - Guangzhou Pharmaceutical Group intends to acquire controlling stakes in Da An Gene, potentially becoming the indirect controlling shareholder with 26.63% of the total share capital [1] Group 1: Acquisition Details - On November 15, 2025, Guangzhou Jin Kong Group, Guangzhou Health Industry Investment, and Guangzhou Pharmaceutical Group signed a framework agreement for the acquisition of Da An Gene's controlling rights [1] - Guangzhou Pharmaceutical Group plans to acquire 100% equity of Guangyong Technology held by Guangzhou Jin Kong Group, which indirectly controls 233 million shares of Da An Gene [1] - Additionally, Guangzhou Pharmaceutical Group will acquire 70.1723 million shares of Da An Gene from both Guangzhou Jin Kong Group and Guangzhou Health Industry Investment through a separate agreement [1] Group 2: Shareholding Impact - Upon completion of the transaction, Guangzhou Pharmaceutical Group will control a total of 374 million shares of Da An Gene, representing 26.63% of the company's total share capital [1]